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Abstract
Background: The multifactorial mechanisms driving negative health outcomes among risky drinkers with HIV may
include immunosenescence. Immunosenescence, aging of the immune system, may be accentuated in HIV and
leads to poor outcomes. The liver regulates innate immunity and adaptive immune tolerance. HIV-infected people
have high prevalence of liver-related comorbidities. We hypothesize that advanced liver fibrosis/cirrhosis is
associated with alterations in T-cell subsets consistent with immunosenescence.
Methods: ART-naïve people with HIV with a recent history of heavy drinking were recruited into a clinical trial of
zinc supplementation. Flow cytometry was used to characterize T-cell subsets. The two primary dependent variables
were CD8+ and CD4+ T-cells expressing CD28-CD57+ (senescent cell phenotype). Secondary dependent variables
were CD8+ and CD4+ T-cells expressing CD45RO + CD45RA- (memory phenotype), CD45RO-CD45RA+ (naïve
phenotype), and the naïve phenotype to memory phenotype T-cell ratio (lower ratios associated with
immunosenescence). Advanced liver fibrosis/cirrhosis was defined as FIB-4 > 3.25, APRI≥1.5, or Fibroscan
measurement ≥10.5 kPa. Analyses were conducted using multiple linear regression adjusted for potential
confounders.
Results: Mean age was 34 years; 25% female; 88% hepatitis C. Those with advanced liver fibrosis/cirrhosis (N = 25)
had higher HIV-1 RNA and more hepatitis C. Advanced liver fibrosis/cirrhosis was not significantly associated with
primary or secondary outcomes in adjusted analyses.
Conclusions: Advanced liver fibrosis/cirrhosis was not significantly associated with these senescent T-cell
phenotypes in this exploratory study of recent drinkers with HIV. Future studies should assess whether liver fibrosis
among those with HIV viral suppression and more advanced, longstanding liver disease is associated with changes
in these and other potentially senescent T-cell subsets.
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Background
Heavy alcohol use is more prevalent among people living
with human immunodeficiency virus/acquired immuno-
deficiency syndrome (PLWHA) than among uninfected
people [1] and is associated with liver disease and multiple
negative health outcomes [2]. Alcohol related liver injury
among PLWHA is compounded by high prevalence of
liver-related comorbidities occurring among PLWHA
such as viral hepatitis. The multifactorial mechanisms
driving negative health outcomes among PLWHA who
are risky drinkers are still being elucidated [3–7].
The liver plays a critical role in metabolic detoxifica-
tion and immune regulation [8]. It receives blood from
the hepatic arteries and the portal venous system. Blood
from the portal venous system contains nutrients, meta-
bolic products as well as toxins and antigens. Thus, the
liver must balance immune activation from antigen ex-
posure with preventing damage to hepatocytes and sur-
rounding tissues from the antigenic response.
We hypothesize that fibrotic or cirrhotic livers of
PLWHA have diminished capability to maintain this bal-
ance, resulting in chronic immune activation and ultim-
ately, premature immune exhaustion (immunosenescence).
The objective of this study is therefore to explore the asso-
ciation between advanced liver fibrosis/cirrhosis and alter-
ations in T-cell subsets among ART-naïve HIV-infected
Russians with heavy alcohol consumption.
Methods
Participants
Study participants were from the Russia ARCH (Alcohol
Research Collaboration on HIV/AIDS) and ZINC HIV
(Zinc for INflammation and Chronic disease in HIV)
studies. Russia ARCH is a longitudinal cohort of
PLWHA with varying levels of alcohol consumption.
ZINC HIV is a randomized double-blinded placebo con-
trolled clinical trial (ClinicalTrials.gov identifier:
NCT01614626). The aim of ZINC HIV is to determine
the efficacy of long-term zinc supplementation com-
pared to placebo among PLWHA on outcomes related
to mortality risk, cardiovascular disease risk, microbial
translocation, inflammation and HIV disease progression
[9]. Participants in the ZINC HIV trial were antiretro-
viral therapy naïve at enrollment and reported heavy
drinking within the 30 days prior to enrollment. Heavy
drinking was defined according to National Institutes on
Alcohol Abuse and Alcoholism (NIAAA) risky drinking
criteria as > 4 standard drinks in a day (or > 14 standard
drinks/week) for men and > 3/ day (or > 7/week) for
women. The first 250 participants in Russia ARCH had
T-cell phenotyping by flow cytometry. All ZINC partici-
pants had liver enzymes and platelets measured and
Fibroscan imaging performed. The current study focuses
on the overlapping subset of participants in both Russia
ARCH and ZINC who had available liver fibrosis data
and T-cell phenotypes at baseline (N = 130).
Main independent variable
The main exposure variable was advanced liver fibrosis/
cirrhosis defined as having any of the following: FIB-4
score > 3.25, APRI score ≥ 1.5 or Fibroscan result ≥10.5
kPa [10, 11]. The FIB-4 score is calculated as the prod-
uct of age (years) and aspartate aminotransferase (AST,
U/L) divided by the product of platelet count (109/L)
and the square root of alanine aminotransferase (ALT,
U/L). The resulting score was categorized as ≤3.25 (no
advanced fibrosis/cirrhosis) or > 3.25 (advanced fibrosis/
cirrhosis). The APRI score is calculated as AST divided
by platelet count and categorized such that scores
greater than or equal to 1.5 reflect advanced fibrosis/cir-
rhosis. By design in the ZINC HIV trial, participants
with FIB-4 in the indeterminate range (i.e., 1.45 to 3.25)
received Fibroscan imaging. Fibroscan enables ultra-
sound measurement of liver stiffness, which correlates
with liver fibrosis. These data were used to confirm ad-
equate separation of liver fibrosis exposure groups
among the subset of participants on whom Fibroscan
imaging was done.
Outcome variable
We analyzed CD8+ and CD4+ T-cell phenotypes con-
sistent with immunosenescence, the aging related de-
cline of adaptive immune function. Immunosenescence
is characterized by accumulation of CD28-CD57+ T-
cells, decrease in naïve lymphocytes, and increase in
memory lymphocytes that are oligoclonally expanded,
resistant to apoptosis and functionally incompetent [12,
13]. The two primary outcomes were the percentage of
CD8+ and CD4+ T-cells expressing the CD28-CD57+
phenotype. T-cells that lose CD28 (CD28-) or gain
CD57 (CD57+) expression have undergone chronic anti-
genic stimulation, multiple rounds of antigen-specific
replication, and have decreased ability to replicate fur-
ther. These T-cell subsets are cytotoxic or immunosup-
pressive, and poorly regulated [14]. The CD28-CD57+
phenotype is associated with alcoholism [15], intracellu-
lar infections like HIV, [16, 17] and diseases of aging like
cancer [14]. Six secondary outcomes were evaluated:
CD8+ and CD4+ T-cells expressing CD45RO +
CD45RA- (memory phenotype), CD45RO-CD45RA+
(naïve phenotype), or naïve:memory T-cell ratio (lower
ratios associated with immunosenescence). Skewed out-
comes were natural log-transformed to better approxi-
mate a normal distribution.
Flow cytometry and T-cell quantification have been
previously described [18]. Briefly, heparin anticoagulated
whole blood was processed within 4 h of collection at
the St. Petersburg Pasteur Institute Central Clinical
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Diagnostic Laboratory. All reagents were from BD Bio-
sciences. Whole blood was labeled with FITC anti-CD8,
PE anti-CD45RO, PeCy5 anti-CD45RA and APC-H7
anti-CD4, or FITC anti-CD8, PE anti-CD57, PeCy5 anti-
CD28 and APC-H7 anti CD4 or appropriate isotypes.
Samples were incubated, red blood cells were lysed, cells
were washed, and samples were fixed in paraformalde-
hyde. Flow cytometry was performed on a BD FACS
Cantos that has been calibrated daily and compensation
was set using single color controls. Flow data was ana-
lyzed with BD FACS DIVA software. Lymphocytes were
gated based on their forward and side scatter. CD4+ and
CD8+ cells are reported as a percent of gated lympho-
cytes. All other subsets are a percent of either CD4+ or
CD8+ cells.
Covariates
This study used covariate data obtained from the follow-
ing instruments: 30 Day Timeline Follow Back for alco-
hol use, [19] Fagerström Test for Nicotine Dependence,
[20] survey of co-morbidities adapted from the Veterans
Aging Cohort Study patient questionnaire [21] and HIV
Risk Behavior Survey (RBS) [22]. Past 30-day heavy
drinking was based on Timeline Followback for alcohol
use and categorized per NIAAA risky drinking criteria.
HIV RNA was quantified using a polymerase chain
reaction-based diagnostic (AmpliSens® HIVMonitor-
FRT, Amplisens, Moscow, Russia). Hepatitis C status
was based on an antibody test. Past 30-day injection
drug use, current smoking and prior exposure to poten-
tially chronic infections (hepatitis B, tuberculosis, herpes
zoster) were based on self-report. Covariates were poten-
tial confounders selected a priori based on the literature
and clinical knowledge.
Statistical analysis
For descriptive purposes, we compared participant char-
acteristics at baseline by FIB-4 category (no/moderate fi-
brosis vs. advanced fibrosis/cirrhosis) using t-tests,
Wilcoxon rank sum, chi-square or Fisher’s exact tests as
appropriate. Primary and secondary outcomes were
compared between the FIB-4 categories of interest using
multiple linear regression adjusted for potential con-
founders. Regression models were adjusted for age, sex,
HIV-1 RNA, injection drug use in the prior 30 days,
current smoking, time since HIV diagnosis, hepatitis C,
and exposure to chronic infections (hepatitis B, tubercu-
losis, herpes zoster). CD8+ and CD4+ naïve to memory
ratios and CD4 + CD28-CD57+ T-cell subsets were nat-
ural log-transformed to improve normality and back-
transformed for ease of interpretation. For back trans-
formed T-cell subsets, measures of effect are reported as
a ratio of means for comparisons between those with ad-
vanced fibrosis/cirrhosis compared to those without.
Confirmatory analyses were performed using median re-
gression models, which are more robust to departures
from normality and the presence of outliers than linear
regression models [23, 24]. Additional exploratory ana-
lyses were conducted evaluating FIB-4 as a continuous
variable. As an initial step, generalized additive models
(GAMs) were used to assess the form of the relationship
between FIB-4 and outcomes and whether the linearity
assumption was appropriate. Based on the GAMs, linear
or piecewise linear regression models were then used to
evaluate whether FIB-4 was associated with CD4 +
CD28-CD57+ and CD8 + CD28-CD57+ T-cell subsets.
For example, in the analyses of the association between
FIB-4 and CD8 + CD28-CD57+ T-cells, the GAM sug-
gested separate slopes at a FIB-4 value of approximately
2.7. We therefore subsequently fit a piecewise linear re-
gression model estimating separate slopes for those with
FIB-4 less than or equal to 2.7 versus those above this
threshold and tested each slope separately. Analyses
were performed with SAS 9.3 statistical software. The
datasets used and/or analyzed during the current study
are available from the corresponding author on reason-
able request.
Results
Among the 130 participants included in the current
study, 25 (19%) were categorized as having evidence of
advanced liver fibrosis/cirrhosis (Table 1). The partici-
pants were all Caucasian, predominantly younger men
(mean age 34 years) with high prevalence of heavy drink-
ing (90%), hepatitis C antibody positivity (85%) and
mean time since HIV diagnosis of 7 years. Mean log10
HIV-1 RNA copies/mL was 4.5. Those with advanced
liver fibrosis/cirrhosis had more prevalent hepatitis C
co-infection. Among those with Fibroscan data, median
Fibroscan scores were higher among those with evidence
of liver fibrosis compared to those without (8.0 vs. 6.2)
(p < 0.05 for comparisons by liver fibrosis category).
In unadjusted analyses, the proportions of senescent,
memory and naïve CD8+ and CD4+ T-cells were similar
by liver fibrosis category (Tables 2, 3, 4, and 5; p > 0.05).
All associations remained non-significant after adjust-
ment for possible confounders (Tables 4 and 5). In
adjusted analyses of the two primary outcomes, the pro-
portion of CD8 + CD28-CD57+ T-cells was lower among
those with advanced liver fibrosis/cirrhosis, but the dif-
ference was not statistically significant (adjusted mean
difference [95% confidence interval, CI]: − 0.36 [− 7.35,
6.63]. CD4 + CD28-CD57+ T-cells proportion was simi-
lar for the two groups (adjusted ratio of means [95% CI]:
1.00 [0.48, 2.07]). For this and other back transformed
T-cell subsets, the ratio of means is interpreted as fol-
lows: mean proportion of T-cell subset in the advanced
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liver fibrosis/cirrhosis group compared to the group
without advanced liver fibrosis/cirrhosis.
In secondary analyses, the ratio of naïve:memory
CD8+ T-cells was higher for those with advanced
liver fibrosis/cirrhosis (adjusted ratio of means [95%
CI]: 1.32 [0.88, 1.97]). The ratio of naïve:memory
CD4+ T-cells was similar for the two groups (ad-
justed ratio of means [95% CI]: 1.00 [0.66, 1.52]).
Confirmatory analysis with median regression for
CD4 + CD28-CD57+ T-cells yielded results consistent
with the primary analyses.
In exploratory analyses of FIB-4 as a continuous vari-
able, a piecewise linear model was fit for the outcome
CD8 + CD28-CD57+ T-cells. Although the observed
slope for FIB-4 was positive at lower levels of FIB-4 and
negative for higher levels of FIB-4, neither reached stat-
istical significance (Table 6). For the outcome CD4 +
CD28-CD57+ T-cells, a linear model was fit based on
the GAM, and no significant association was observed
for FIB-4.
Discussion
In this exploratory study of ART-naïve PLWHA with
heavy drinking, those with advanced liver fibrosis/cirrho-
sis appeared to have lower prevalence of CD8+ T-cell
phenotypes suggestive of immunosenescence (i.e. lower
proportions CD8 + CD28-CD57+, higher naïve:memory
Table 1 Baseline characteristics of study population by liver fibrosis status among ART-naïve people living with HIV/AIDS (PLWHA)






N 130 105 25 –
Mean age (SD)/years 33.5 (6.0) 33.6 (6.2) 33.1 (4.9) 0.74
Female sex 33 (25%) 26 (25%) 7 (28%) 0.74
Heavy drinkinga 118 (91%) 95 (90%) 23 (92%) 0.81
Injected drugs use (past 30 days) 46 (35%) 38 (36%) 8 (32%) 0.69
Current regular smoker 111 (85%) 87 (83%) 24 (96%) 0.09
Self-reported history of hepatitis B 43 (33%) 34 (32%) 9 (36%) 0.73
Self-reported history of herpes zoster 28 (22%) 20 (19%) 8 (32%) 0.16
Self-reported history of tuberculosis 16 (12%) 11 (11%) 5 (20%) 0.19
Hepatitis C antibody positive 114 (88%) 89 (85%) 25 (100%) 0.04
Mean years since first positive HIV test (SD) 6.8 (5.0) 6.7 (4.9) 7.3 (5.4) 0.54
Mean platelet count (SD) 211 (74) 226 (65) 148 (75) < 0.01
Mean ALT (SD)/Units per liter 52 (74) 38 (40) 109 (136) < 0.01
Mean AST (SD)/Units per liter 65 (65) 45 (22) 148 (107) < 0.01
Median FIB-4 (25th, 75th) 1.3 [0.9, 2.1] 1.1 [0.9, 1.5] 3.4 [2.3, 6.6] < 0.01
Median APRI (25th, 75th) 0.6 [0.4, 1.0] 0.5 [0.3, 0.8] 2.4 [1.5, 4.2] < 0.01
Median Fibroscan (25th, 75th); N = 33 (9 determined to have advanced fibrosis/cirrhosis) 6.4 [5.3, 8.4] 6.2 [5.0, 7.2] 8.0 [7.6, 13.6] < 0.01
Mean Log10 HVL (SD) /copies/mL 4.5 (1.1) 4.5 (1.0) 4.6 (1.3) 0.85
a heavy drinking (> 4 standard drinks in a day (or > 14 standard drinks/week) for men and > 3/ day (or > 7/week) for women)
Data are N(%) unless otherwise specified.
Table 2 Distribution of CD8+ T-cell subsets reflecting immunosenesence by liver fibrosis status among art-naïve PLWHA with recent
heavy alcohol use
T-cell subsets as a proportion of CD8+ T-
cells
Mean (SD) unless otherwise stated p-value
Overall No advanced fibrosis/cirrhosis Advanced fibrosis/cirrhosis
CD8 + CD28-CD57+ 35.6 (15.7) 35.4 (15.5) 36.1 (16.7) 0.85
CD8+ memory 34.4 (13.8) 34.9 (13.7) 32.3 (14.4) 0.40
CD8+ naive 38.7 (15.0) 39.3 (14.0) 36.4 (18.6) 0.44
CD8 naïve:memory ratio median (25th, 75th) 1.56 (0.99, 2.40) 1.54 (0.95, 2.30) 1.82 (1.17, 3.00) 0.26
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CD8+ T-cell ratio). However, these differences did not
reach statistical significance.
To our knowledge, no published studies have assessed
these T-cell subpopulations by liver fibrosis status
among HIV infected people. A prior study described
similar memory (CD45RO+) T-cell proportions among
HIV uninfected patients with cirrhosis compared to
healthy controls, which is consistent with our results.
Markers of immunosenescence in that study were in-
creased in cirrhosis patients compared to healthy con-
trols (i.e., higher proportion of CD8 + CD45RO + CD57+
T-cells) and in cirrhotic patients with ascites compared
to healthy controls (i.e., lower proportion of CD28+ T-
cells) [25]. Others have reported evidence of immunose-
nescence (i.e., lower CD8 + CD28+ T-cell proportions)
among HIV uninfected people with cirrhosis who
Table 3 Distribution of CD4+ T-cell subsets reflecting immunosenesence by liver fibrosis status among art-naïve PLWHA with recent
heavy alcohol use
T-cell subsets as a proportion
of CD4+ T-cells
Mean (SD) unless otherwise stated p-value
Overall No advanced fibrosis/cirrhosis Advanced fibrosis/cirrhosis
CD4 + CD28-CD57+
(25th, 75th)
2.25 (0.40, 6.40) 2.40 (0.40, 6.10) 1.40 (0.40, 6.60) 0.59
CD4+ memory 54.3 (16.3) 53.7 (15.1) 56.6 (20.7) 0.42
CD4+ naive 38.7 (15.0) 39.3 (14.0) 36.4 (18.6) 0.39
CD4+ naïve:memory ratiomedian
(25th, 75th)
0.70 (0.48, 1.07) 0.75 (0.48, 1.13) 0.59 (0.47, 1.06) 0.81
Table 4 a) Unadjusted and b)adjusted association between liver fibrosis status and CD8+ T-cell subsets reflecting immunosenesence
among art-naïve PLWHA with recent heavy alcohol use
a) CD8+ CD28- CD57+
(as % of CD8+)
CD8+ Memory
(as % of CD8+)












1 (referent group) 1 (referent group) 1 (referent group) 1 (referent group)
Advanced
fibrosis/ cirrhosis
0.67 (−6.15, 7.48) 0.85 −2.61 (−8.59, 3.36) 0.39 2.48 (−3.78, 8.73) 0.44 1.24 (0.84, 1.90) 0.25
b) CD8+ CD28- CD57+ (as
%CD8+)












1 (referent group) 1 (referent group) 1 (referent group) 1 (referent group)
Advanced fibrosis/
cirrhosis (adjusted)
−0.36 (−7.35, 6.63) 0.92 −3.16 (−8.90, 2.57) 0.28 3.07 (−2.97, 9.11) 0.32 1.32 (0.88, 1.97) 0.18
Age/years −0.07 (− 0.39, 0.53) 0.77 − 0.15 (− 0.53, 0.23) 0.45 0.01 (− 0.39, 0.41) 0.96 1.00 (0.97, 1.03) 0.96
Female sex −0.53 (−6.93, 5.87) 0.87 −3.12 (− 8.37, 2.13) 0.24 2.76 (−2.76, 8.29) 0.33 1.23 (0.85, 1.78) 0.27
Log10(HIV-1 RNA copies/
mL)
−0.18 (−2.70, 2.34) 0.89 2.94 (0.87, 5.01) < 0.01 −2.38 (−4.55, − 0.20) 0.03 0.91 (0.79, 1.05) 0.20
Heavy drinking −0.15 (−9.45, 9.16) 0.98 −6.68 (−14.32, 0.95) 0.09 8.27 (0.23, 16.30) 0.04 1.47 (0.86, 2.51) 0.16
Injection drug use 3.26 (−3.08, 9.60) 0.31 −1.10 (−6.31, 4.10) 0.68 2.95 (−2.53, 8.42) 0.29 1.26 (0.87, 1.81) 0.22
Current smoking −0.17 (−8.51, 8.18) 0.97 5.31 (−1.53, 12.16) 0.13 −5.58 (− 12.79, 1.63) 0.13 0.74 (0.46, 1.20) 0.23
Years since HIV
diagnosis
−0.16 (− 0.72, 0.41) 0.59 − 0.24 (− 0.70, 0.22) 0.31 0.65 (0.16, 1.14) < 0.01 1.03 (1.00, 1.07) 0.07
Hepatitis C 6.67 (−2.29, 15.63) 0.14 1.5 (−5.84, 8.86) 0.69 −2.93 (−10.7, 4.81) 0.46 0.89 (0.53, 1.48) 0.65
Hepatitis B −3.41 (−9.68, 2.86) 0.29 4.72 (−0.42, 9.87) 0.07 −5.55 (−11.0, − 0.13) 0.04 0.67 (0.47, 0.97) 0.03
Shingles 1.70 (−5.02, 8.43) 0.62 3.04 (−2.48, 8.55) 0.28 −1.64 (−7.44, 4.17) 0.58 0.85 (0.58, 1.25) 0.41
Tuberculosis 2.43 (−6.07, 10.93) 0.58 −8.60 (−15.57, − 1.62) 0.02 6.07 (− 1.27, 13.41) 0.11 1.46 (0.89, 2.37) 0.13
aResult after back transformation from natural log scale
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consumed > 90 g/day of ethanol in prior 5 years com-
pared to healthy controls consuming 10-15 g/day ethanol
[26]. These findings may differ from ours because: 1)
our study was conducted among PLWHA; 2) we investi-
gated different subsets of T-cells representing immuno-
senescence; and 3) we had few people with cirrhosis and
did not have data about ascites.
HIV and viral hepatitis have each been shown to be asso-
ciated with markers of cellular immunosenescence. Since all
participants in the current study were ART-naïve PLWHA
and most were hepatitis C co-infected, it is plausible that the
effects of HIV and hepatitis C infection on the T-cell subsets
we assessed may be masking a potential effect of liver fibro-
sis on these cell populations. Evidence for this is provided by
the associations we observed linking HIV-1 RNA and hepa-
titis C co-infection with CD8+ and CD4+ T-cell subsets re-
spectively. Future studies should repeat these analyses
among HIV infected people with suppressed viremia.
Another potential reason these results do not confirm
our hypothesis involves the regenerative capability of the
liver. Many of the participants in the prior studies where
differences in T-cell subsets were observed had biopsy
confirmed cirrhosis and/or ascites. It is possible that a
much greater degree and chronicity of liver fibrosis or
cirrhosis than was present in our cohort, is required be-
fore differences demonstrating senescence in T-cell sub-
sets will be observed. If this were to be true, it would
suggest that subclinical measures of liver fibrosis as used
in this study may not be able to identify if the liver is
losing its ability to regulate immune activation and
maintain immune tolerance. Alternatively, it could also
suggest that a longer duration of liver fibrosis may be re-
quired before subclinical measures of liver fibrosis can
provide information about senescence.
Our exploratory analyses suggest the importance of
considering non-linear associations between liver disease
and T-cell subsets consistent with immunosenescence.
While FIB-4 of 3.25 is an important clinical threshold
for advanced fibrosis/cirrhosis, there is ambiguity in
interpreting FIB-4 between 1.45 and 3.25. Our analyses
Table 5 a) Unadjusted and b) adjusted association between liver fibrosis status and CD4+ T-cell subsets reflecting
immunosenesence among art-naïve PLWHA with recent heavy alcohol use
a) CD4+ CD28- CD57+
(as % of CD4+)
CD4+ Memory
(as % of CD4+)
CD4+ Naïve













1 (referent group) 1 (referent group) 1 (referent group) 1 (referent group)
Advanced fibrosis/
cirrhosis
0.81 (0.39, 1.70) 0.58 2.95 (−4.09, 10.0) 0.41 −3.83 (−9.28, 1.61) 0.17 0.95 (0.63, 1.44) 0.81
b) CD4+ CD28- CD57+
(as % of CD4+)
CD4+ Memory
(as % of CD4+)
CD4+ Naïve















1 (referent group) 1 (referent group) 1 (referent group) 1 (referent group)
Advanced fibrosis/
cirrhosis
1.00 (0.48, 2.07) 1.00 2.15 (−4.89, 9.19) 0.55 −3.38 (−8.67, 1.91) 0.21 1.00 (0.66, 1.52) 0.99
Age/years 1.05 (1.00, 1.10) 0.07 0.32 (−0.15, 0.79) 0.18 −0.37 (− 0.79, 0.04) 0.08 0.98 (0.96, 1.01) 0.22
Female sex 0.89 (0.46, 1.73) 0.73 −2.42 (−8.86, 4.02) 0.46 2.97 (− 2.62, 8.57) 0.30 1.14 (0.78, 1.67) 0.49
Log10(HIV-1 RNA) 0.91 (0.70, 1.18) 0.49 0.79 (−1.75, 3.33) 0.54 −0.59 (− 2.58, 1.41) 0.56 1.00 (0.86, 1.17) 0.96
Heavy drinking 0.91 (0.34, 2.39) 0.84 −4.87 (−14.23, 4.50) 0.31 5.36 (−2.71, 13.43) 0.19 1.27 (0.73, 2.21) 0.40
Injection drug use 1.09 (0.56, 2.11) 0.80 −3.11 (−9.50, 3.27) 0.34 3.53 (−1.9, 8.96) 0.20 1.16 (0.80, 1.69) 0.43
Current smoking 0.80 (0.34, 1.91) 0.62 1.75 (−6.65, 10.15) 0.68 −2.3 (−9.75, 5.16) 0.55 0.92 (0.56, 1.51) 0.73
Years since HIV
diagnosis
0.98 (0.93, 1.04) 0.55 −0.06 (− 0.63, 0.51) 0.83 0.11 (− 0.38, 0.6) 0.66 1.00 (0.97, 1.04) 0.83
Hepatitis C 0.37 (0.14, 0.93) 0.04 −2.57 (−11.59, 6.45) 0.58 3.49 (−4.52, 11.5) 0.39 1.14 (0.67, 1.94) 0.63
Hepatitis B 0.62 (0.32, 1.19) 0.15 5.69 (−0.62, 12.01) 0.08 −5.04 (−10.39, 0.3) 0.06 0.74 (0.51, 1.07) 0.11
Shingles 1.41 (0.70, 2.84) 0.34 6.13 (−0.63, 12.90) 0.08 −5.51 (−11.32, 0.31) 0.06 0.71 (0.47, 1.05) 0.09
Tuberculosis 0.93 (0.38, 2.24) 0.86 1.45 (−7.10, 10.01) 0.74 −3.64 (−10.84, 3.56) 0.32 0.82 (0.50, 1.37) 0.46
aRepresents the ratio of means after back transformation from natural log scale
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suggest that the relationship between FIB-4 and CD8+
T-cells with senescent characteristics could potentially
vary within this indeterminate range. Future studies link-
ing liver disease and T-cell dysfunction should examine
this further and account for the possibility of non-linear
associations.
Limitations to this work that warrant discussion. Cur-
rently, more detailed markers of immunosenescence and
memory and naïve T-cell phenotypes available than were
readily available at the time of our flow cytometry test-
ing between 2013 and 2015. Our analysis only examined
T-cell phenotypes as percentages of CD4 or CD8, where
an absolute count, which was unavailable, might yield
different conclusions. Imaging confirmation of liver
fibrosis was only available for a subset of our partici-
pants. In this subset however, Fibroscan data suggest we
achieved good separation of the liver fibrosis exposure
groups we defined. Several of our covariates were self-
reported, without information on duration of co-morbid
conditions, and subject to reporting bias. However, the
several potential confounders (e.g. alcohol, HIV viremia,
hepatitis C status) were measured using validated instru-
ments and/or objective laboratory data. This study was
likely underpowered to detect the associations of interest
and as such should be considered exploratory and hypoth-
esis generating. Post hoc power calculations based on the
observed standard deviations in each group indicate we
had approximately 80% power to detect a minimum dif-
ference in CD8 + CD28-CD57+ T-cell proportions of 10, a
substantially larger mean difference than the 0.7 observed
in this study. As with all observational studies, there is a
possibility of unmeasured confounding.
Conclusions
We did not detect a significant association between ad-
vanced liver fibrosis/cirrhosis and the senescent T-cell
phenotypes assessed in this sample of ART-naïve HIV-
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Table 6 Association between liver fibrosis status (continuous
measure) and a) CD8+ T-cell b) CD4+ T-cell subsets reflecting
immunosenesence among art-naïve PLWHA with recent heavy
alcohol use
a) CD8+ CD28- CD57+ (as % of CD8+)
Adjusted Mean Difference (95% CI) P-value
Log(FIB-4)≤ 1 6.2 (− 0.70, 13.18) 0.08
Log(FIB-4) > 1 −5.54 (− 13.6, 2.47) 0.17
Age/years −0.06 (− 0.58, 0.45) 0.80
Female sex −0.83 (−7.68, 6.01) 0.81
Log10(HIV-1 RNA) −0.45 (− 3.15, 2.25) 0.74
Heavy drinking 1.24 (−8.99, 11.47) 0.81
Injection drug use 3.54 (−3.12, 10.20) 0.30
Current smoking −0.55 (−9.53, 8.43) 0.90
Years since HIV diagnosis −0.08 (− 0.68, 0.52) 0.79
Hepatitis C 4.32 (−5.33, 13.97) 0.38
Hepatitis B −3.69 (− 10.34, 2.97) 0.27
Shingles 0.32 (−6.82, 7.46) 0.93
Tuberculosis 3.11 (−5.82, 12.04) 0.49
b) CD4+ CD28- CD57+ (as% of CD4+)
Adjusted Mean Difference (95% CI) P-value
Log(FIB-4) 0.99 (0.64, 1.54) 0.97
Age/years 1.05 (0.99, 1.10) 0.09
Female sex 0.83 (0.41, 1.71) 0.62
Log10(HIV-1 RNA) 0.90 (0.68, 1.20) 0.48
Heavy drinking 1.07 (0.37, 3.14) 0.90
Injection drug use 1.09 (0.54, 2.19) 0.81
Current smoking 0.89 (0.35, 2.27) 0.80
Years since HIV diagnosis 0.99 (0.93, 1.05) 0.68
Hepatitis C 0.34 (0.13, 0.93) 0.04
Hepatitis B 0.62 (0.31, 1.24) 0.18
Shingles 1.34 (0.63, 2.81) 0.44
Tuberculosis 0.92 (0.36, 2.36) 0.87
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